THE PERIPHERAL BLOOD LEUKOCYTES SUSCEPTIBILITY TO INTERFERON-α2 IN VITRO CHANGE AMONGST CHILDREN WITH INFECTIOUS MONONUCLEOSIS

Cover Page


Cite item

Full Text

Abstract

Objective: to measure cell susceptibility of peripheral blood leukocytes to interferon-α2 in vitro at children during the acute period in 1 and 6 months after infectious mononucleosis caused by the Epstein–Barr virus. 47 children aged 4–6 years with moderately severe form of the disease in the acute period of infectious mononucleosis caused by the Epstein–Barr virus (EBV) were examined, as well as in 1 month (n = 17) and 6 months (n = 11) after the disease. The focus group consisted of 36 nearly healthy children. The cell susceptibility to interferon-α2 in vitro was determined by the method of Kurtasova L.M. et al. (2007). Chemiluminescence of blood leukocytes was studied by De Sole et al. (1983). The susceptibility change of peripheral blood leukocytes to interferon-α2 in vitro at children with infectious mononucleosis caused by Epstein–Barr virus in dynamics of the disease has been revealed. The expansion of the range of cell susceptibility to interferon-α2 in 6 months after the disease has been enclosed. The dependence of the susceptibility of peripheral blood leukocytes to interferon-α2 in vitro on the dose and the period of the disease has been fixed.

About the authors

L. M. Kurtasova

Krasnoyarsk State Medical University named after professor V.F. Voyno-Yasenetsky of the Ministry of Health of the Russian Federation

Author for correspondence.
Email: sibmed-obozrenie@yandex.ru

PhD, MD (Medicine), Professor of the Department of Clinical Immunology

660022, Russian Federation, Krasnoyarsk, Partizanа Zheleznyaka str., 1, Phone: +7 (391) 220-06-28

Russian Federation

N. A. Shakina

Krasnoyarsk Regional Center for Prevention and Control of AIDS

Email: fake@neicon.ru

PhD (Medicine), Head of the Department of Immunological Studies

Russian Federation

L. A. Ikkes

Krasnoyarsk State Medical University named after professor V.F. Voyno-Yasenetsky of the Ministry of Health of the Russian Federation

Email: fake@neicon.ru

Resident Physician, Department of Pediatric Infectious Diseases

Russian Federation

References

  1. Гончарова Е.В., Сенюта Н.Б., Смирнова К.В., Щербак Л.Н., Гурцевич В.Э. Вирус Эпштейна–Барр (ВЭБ) в России: инфицированность населения и анализ вариантов гена LMP1у больных ВЭБ-ассоциированными патологиями и у здоровых лиц // Вопросы вирусологии. 2015. Т. 60, № 2. С. 11–17. [Goncharova E.V., Senyuta N.B., Smirnov K.V., Shcherbak L.N., Gurtsevich V.E. Epstein–Barr virus (EBV) in Russia, the infection of the population and the analysis of gene LMP1 variants at the patients with EBV-associated disease and at healthy patients. Voprosy virusologii = Problems of Virology, 2015, vol. 60, no. 2, pp. 11–17. (In Russ.)]
  2. Ершов Ф.И., Киселев О.И. Интерфероны и их индукторы. Москва: ГЭОТАР-Медиа, 2005. 368 с. [Ershov F.I., Kiselev O.I. Interferony i ikh induktory [Interferons and their inducers]. Moscow: GEOTAR-Media, 2005. 368 p.]
  3. Кетлинский С.А., Симбирцев А.С. Цитокины. СПб.: Фолиант, 2008. 550 с. [Ketlinsky S.A., Simbirtsev A.S. Tsitokiny [Cytokines]. SPb.: Foliant, 2008. 550 p.]
  4. Куртасова Л.М., Ольховский И.А., Якунина Е.Ю., Голованова А.Е., Заблоцкая С.Г. Клиническое значение иммунологических маркеров ВЭБ-инфекции при инфекционном мононуклеозе у детей // Клиническая лабораторная диагностика. 2005. № 12. С. 44–46. [Kurtasova L.M., Olkhovskiy I.A., Yakunina E.Y., Golovanova A.E., Zablotskaya S.G. The clinical significance of immunological markers of EBV-infection with infectious mononucleosis at children. Klinicheskaya laboratornaya diagnostika = Clinical Laboratory Diagnostics, 2005, no. 12, pp. 44–46. (In Russ.)]
  5. Львов Н.Д., Дудукина Е.А. Ключевые вопросы диагностики Эпштейна–Барр вирусной инфекции // Инфекционные болезни. Журнал для непрерывного медицинского образования врачей. 2013. № 3. С. 24–32. [Lvov N.D., Dudukina E.A. Key questions of the Epstein–Barr virus infection diagnostics. Infectious diseases. Infektsionnye bolezni. Zhurnal dlya nepreryvnogo meditsinskogo obrazovaniya vrachei = The Journal of Continuing Medical Education for Physicians, 2013, no. 3, pp. 24–32. (In Russ.)]
  6. Патент 2293988 Российской Федерации, МПК G01N 33/50 (2006.01). Способ оценки чувствительности к интерферону у больных раком почки / Куртасова Л.М., Шкапова Е.А., Савченко А.А., Крыжановский А.И., Зуков Р.А., Рачкова Н.В.; заявитель и патентообладатель: ГУ НИИ медицинских проблем Севера СО РАМН (RU), Красноярский краевой онкологический диспансер (RU). заявл. 11.01.05; опубл. 20.02.07, Бюл. № 5. 4 с. [Patent 2293988 of Russian Federation. IPC G01N 33/50 (2006.01). Sposob otsenki chuvstvitel’nosti k interferonu u bol’nykh rakom pochki [A method of evaluation of susceptibility to interferon at patients with clear cell carcinoma] / Kurtasova L.M., Shkapova E.A., Savchenko A.A., Krizhanovsky A.I., Zukow R.A., Rachkova N.V.; appl. and patent holder: Research Institute of Medical Problems of the North SB RAMS (RU), Krasnoyarsk Regional Oncology Center (RU); stat. 11.01.05; publ. 20.02.07, Bull. No. 5. 4 p.]
  7. De Sole P., Lippa S., Lixxarru G. Whole blood chemiluminescence: a new technical approach to access oxygen-dependent microbial activity of granulocytes. J. Clin. Lab. Autom., 1983, vol. 3, pp. 391–400.
  8. Odumade O.A., Hogquist K.A., Balfour H.H. Progress and problems in understanding and managing primary Epstein–Barr virus infections. Clin. Microbiol. Rev., 2011, vol. 24, pp. 193–209. doi: 10.1128/CMR.00044-10

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Kurtasova L.M., Shakina N.A., Ikkes L.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 64788 от 02.02.2016.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies